Rosenberg Matthew Hamilton Sells 405 Shares of AstraZeneca PLC (NASDAQ:AZN)

Rosenberg Matthew Hamilton lessened its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 26.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,135 shares of the company’s stock after selling 405 shares during the quarter. Rosenberg Matthew Hamilton’s holdings in AstraZeneca were worth $74,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Tealwood Asset Management Inc. boosted its position in AstraZeneca by 0.8% in the fourth quarter. Tealwood Asset Management Inc. now owns 37,410 shares of the company’s stock valued at $2,451,000 after buying an additional 290 shares in the last quarter. Miracle Mile Advisors LLC boosted its holdings in shares of AstraZeneca by 445.7% in the 4th quarter. Miracle Mile Advisors LLC now owns 39,986 shares of the company’s stock worth $2,620,000 after acquiring an additional 32,659 shares in the last quarter. Sivia Capital Partners LLC boosted its holdings in shares of AstraZeneca by 3.2% in the 4th quarter. Sivia Capital Partners LLC now owns 7,390 shares of the company’s stock worth $484,000 after acquiring an additional 226 shares in the last quarter. Moody National Bank Trust Division increased its holdings in AstraZeneca by 20.0% during the 4th quarter. Moody National Bank Trust Division now owns 4,556 shares of the company’s stock valued at $299,000 after purchasing an additional 758 shares in the last quarter. Finally, Trust Co. of Toledo NA OH increased its holdings in AstraZeneca by 4.6% during the 4th quarter. Trust Co. of Toledo NA OH now owns 7,651 shares of the company’s stock valued at $501,000 after purchasing an additional 337 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Price Performance

AstraZeneca stock opened at $65.37 on Wednesday. The business’s 50-day simple moving average is $65.98 and its 200 day simple moving average is $74.69. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The stock has a market cap of $202.69 billion, a price-to-earnings ratio of 31.28, a P/E/G ratio of 1.19 and a beta of 0.46. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS. As a group, research analysts anticipate that AstraZeneca PLC will post 4.11 earnings per share for the current year.

Wall Street Analyst Weigh In

AZN has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, AstraZeneca has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.